AR020065A1 - Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende - Google Patents
Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprendeInfo
- Publication number
- AR020065A1 AR020065A1 ARP990101578A ARP990101578A AR020065A1 AR 020065 A1 AR020065 A1 AR 020065A1 AR P990101578 A ARP990101578 A AR P990101578A AR P990101578 A ARP990101578 A AR P990101578A AR 020065 A1 AR020065 A1 AR 020065A1
- Authority
- AR
- Argentina
- Prior art keywords
- ylcarbonyl
- thiazol
- leucinyl
- hydrazide
- amino
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- -1 N-benzyloxycarbonylglycinyl Chemical group 0.000 abstract 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 2
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 2
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se refiere a composicion farmacéuticas que inhiben proteasas, tales como las proteasas de cisteína. En particular, se refiere al uso de inhibidores deproteasas de cisteína para la fabricacion de un medicamento para inhibir las proteasas de cisteína,que comprende un compuesto elegido entre el grupo formadopor 2-[N-(N-benciloxicarbonilglicinil)]-2-[N-benciloxicarbonil-L-leucinil)]carbohidrazida; (3RS)-1-(N-benciloxilocarbonil-L-leucinil)-3-[N(4-fenoxibenzoil)amino]pirrolidin-4-ona; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil]]-N-[N-(2-piridinilmetoxicarbonil)-L-leucinil]hidrazida; 1-(N-benciloxicarbonil-L-leucinilamino)-3-(2-benciloxifenilsulfonil)amino-propan-2-ona; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-[N-(3-piridinilmetoxi-carbonil)-L-leucinil]hidrazida; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil-N-[N(3-piridinilmetoxicarbonil)-L-leucinil]]hidrazida; 1-[N-(4-morfolinocarbamoil)-L-leucinilamino]-3-(4-fenoxifenilsulfonil)amino-propan-2-ona; N-[2-(1-naftil)tiazol-4-ilcarbonil]-N-[N-(4-piridinil-metoxicarbonil)-L-leucinil]hidrazida; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-(N-pirazinacarbonil-L-leucinil)hidrazida; N-[N-(1-bencil-5-metilimidazol-4-ilcarbonil)-L-leucinil]-N-[2-(1-naftil)tiazol-4-ilcarbonil]hidrazida; (3RS)-3-[N-(-benciloxibenzoil)-L-leucinilamino]tetrahidrofuran-4-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(5-metil-2-feniloxazol-4-ilcarbonil)-L-leucinil]hidrazida; 1-[3-(2-piridinil)fenilacetamilano]-3-[N-(2-tiofenocarbonil)-L-leucinilamino]propan-2-ona; (3S)-3-[N-(benzotiazol-6-ilcrbonil)-L-leucinilamino]-1-[3-(2-piridinil)fenilacetilamino]butan-2-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(7-metoxibenzofuran-2-ilcarbonil)-L-beta-ciclopropilalanil]hidrazida; 1-[N-(benzoxazol-5-ilcarbonil)-L-leucinilamino]-3-[3-2-piridinil)fenilacetilamino]propan-2-ona; 1-[N-[4-[2-(N,N-dimetilamino)etoxi]benzoil]-L-leucinilamino]-3-[3-(2-piridinil)fenilacetilamino]propan-2-ona; y N-[2-[N-ciclopropil-N-(2-metilpropil)amino)tiazol-4-il-carbonil]-N-[N-[5[2-(N,N-dimetilamino)etoxi]benzofuran-2-ilcarbonil]-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8122198P | 1998-04-09 | 1998-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020065A1 true AR020065A1 (es) | 2002-04-10 |
Family
ID=22162839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101578A AR020065A1 (es) | 1998-04-09 | 1999-04-07 | Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1068304A4 (es) |
| JP (1) | JP2002511491A (es) |
| KR (1) | KR20010042535A (es) |
| CN (1) | CN1304447A (es) |
| AR (1) | AR020065A1 (es) |
| AU (1) | AU3482099A (es) |
| CA (1) | CA2327282A1 (es) |
| CO (1) | CO5080800A1 (es) |
| DZ (1) | DZ2752A1 (es) |
| HU (1) | HUP0101513A2 (es) |
| IL (1) | IL138628A0 (es) |
| MA (1) | MA26618A1 (es) |
| NO (1) | NO20005032L (es) |
| PE (1) | PE20000421A1 (es) |
| PL (1) | PL343373A1 (es) |
| TR (1) | TR200002940T2 (es) |
| WO (1) | WO1999053039A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143742A (en) * | 1997-12-11 | 2000-11-07 | Fuisz Technologies Ltd | Treatment for necrotizing infections |
| DZ2796A1 (fr) * | 1998-05-21 | 2003-12-01 | Smithkline Beecham Corp | Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| WO2000016763A2 (en) | 1998-09-21 | 2000-03-30 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
| EP1488791A3 (en) * | 1998-09-21 | 2005-04-06 | University Of Florida Research Foundation, Inc. | Antimalarial agents |
| CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
| US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034600A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| US6534498B1 (en) | 1999-11-10 | 2003-03-18 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2003513971A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
| AU2001243441B2 (en) | 2000-03-21 | 2004-11-25 | Smithkline Beecham Corporation | Protease inhibitors |
| US6635784B2 (en) | 2000-09-29 | 2003-10-21 | Eastman Chemical Company | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates |
| IL155958A0 (en) * | 2000-11-17 | 2003-12-23 | Medivir Ab | Cysteine protease inhibitors |
| IL156776A0 (en) | 2001-01-17 | 2004-02-08 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
| WO2002057270A1 (en) | 2001-01-17 | 2002-07-25 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
| US7132449B2 (en) * | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
| EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
| WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| BRPI0610644B8 (pt) | 2005-04-04 | 2021-05-25 | Univ Florida | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. |
| BRPI0614169A2 (pt) * | 2005-07-26 | 2016-11-22 | Merck Frosst Canada Ltd | método para tratar uma doença parasítica, e, composição farmacêutica |
| JP5439193B2 (ja) | 2007-03-15 | 2014-03-12 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | デスフェリチオシンポリエーテル類似体 |
| AU2008329515B2 (en) | 2007-11-29 | 2013-09-05 | Merck Canada Inc. | Cysteine protease inhibitors for the treatment of parasitic diseases |
| EP2240491B1 (en) | 2008-01-09 | 2015-07-15 | Amura Therapeutics Limited | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES |
| JP6539046B2 (ja) | 2011-12-16 | 2019-07-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ４’−デスフェリチオシン類似体の使用 |
| EP2633855A1 (en) | 2012-03-01 | 2013-09-04 | Veterinärmedizinische Universität Wien | Protease inhibitors for treating Trichomonas gallinae infections |
| CA2930966A1 (en) | 2013-11-22 | 2015-05-28 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| EP3288557A4 (en) | 2015-04-27 | 2018-11-07 | University of Florida Research Foundation, Inc. | Metabolically programmed metal chelators and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| WO1997016433A1 (en) * | 1995-10-30 | 1997-05-09 | Smithkline Beecham Corporation | Protease inhibitors |
| DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| MA26487A1 (fr) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
-
1999
- 1999-04-05 MA MA25522A patent/MA26618A1/fr unknown
- 1999-04-07 AR ARP990101578A patent/AR020065A1/es unknown
- 1999-04-07 DZ DZ990053A patent/DZ2752A1/xx active
- 1999-04-08 TR TR2000/02940T patent/TR200002940T2/xx unknown
- 1999-04-08 IL IL13862899A patent/IL138628A0/xx unknown
- 1999-04-08 WO PCT/US1999/007723 patent/WO1999053039A1/en not_active Ceased
- 1999-04-08 HU HU0101513A patent/HUP0101513A2/hu unknown
- 1999-04-08 KR KR1020007011178A patent/KR20010042535A/ko not_active Withdrawn
- 1999-04-08 JP JP2000543587A patent/JP2002511491A/ja not_active Withdrawn
- 1999-04-08 CA CA002327282A patent/CA2327282A1/en not_active Abandoned
- 1999-04-08 CN CN99807012A patent/CN1304447A/zh active Pending
- 1999-04-08 AU AU34820/99A patent/AU3482099A/en not_active Abandoned
- 1999-04-08 EP EP99916517A patent/EP1068304A4/en not_active Withdrawn
- 1999-04-08 CO CO99020595A patent/CO5080800A1/es unknown
- 1999-04-08 PL PL99343373A patent/PL343373A1/xx not_active Application Discontinuation
- 1999-04-09 PE PE1999000290A patent/PE20000421A1/es not_active Application Discontinuation
-
2000
- 2000-10-06 NO NO20005032A patent/NO20005032L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1304447A (zh) | 2001-07-18 |
| AU3482099A (en) | 1999-11-01 |
| JP2002511491A (ja) | 2002-04-16 |
| NO20005032L (no) | 2000-11-16 |
| NO20005032D0 (no) | 2000-10-06 |
| EP1068304A1 (en) | 2001-01-17 |
| KR20010042535A (ko) | 2001-05-25 |
| PL343373A1 (en) | 2001-08-13 |
| CA2327282A1 (en) | 1999-10-21 |
| TR200002940T2 (tr) | 2001-02-21 |
| IL138628A0 (en) | 2001-10-31 |
| WO1999053039A1 (en) | 1999-10-21 |
| HUP0101513A2 (hu) | 2001-08-28 |
| DZ2752A1 (fr) | 2003-09-15 |
| CO5080800A1 (es) | 2001-09-25 |
| PE20000421A1 (es) | 2000-05-21 |
| EP1068304A4 (en) | 2001-05-09 |
| MA26618A1 (fr) | 2004-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020065A1 (es) | Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende | |
| RU2368604C2 (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| EA200200975A1 (ru) | Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона | |
| YU7998A (sh) | Heterociklična jedinjenja i njihove farmaceutske kompozicije | |
| ATE244717T1 (de) | Inhibitoren des impdh-enzyms | |
| EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
| AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
| TW200507831A (en) | Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor | |
| IL294247B1 (en) | (2r,4r)-1-(3-chloro-2-fluorobenzyl)-4-((5-fluoro-4-methyl-6-((5-methyl-1h-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid and a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof | |
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| EA200702238A1 (ru) | Комбинация, способ и композиция для лечения рака | |
| MXPA04001364A (es) | Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo. | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| CL2024003456A1 (es) | Formas cristalinas de clorhidrato de envudeucitinib, composición farmacéutica, y uso. | |
| AR014270A1 (es) | Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios | |
| PE20050440A1 (es) | Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas | |
| DE60103284D1 (de) | Antifungizide zusammensetzung von ketoconazole zum auftragen | |
| RU2003115431A (ru) | Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина | |
| TW200501956A (en) | Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine | |
| BR0113713A (pt) | Sal de cloridrato de 5-[4-[2-(metil-n-(2-piridil)amino)etóxi]benzil]tiazolidina -2,4-diona | |
| NO20042871L (no) | Sitronsyre-salt av en terapeutisk forbindelse og farmasoytiske blandinger derav | |
| ATE141248T1 (de) | Neue bis-phenyl-hexene | |
| ECSP034528A (es) | Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona | |
| DK1315724T3 (da) | Thiazolidindionderivat og dets anvendelse som antidiabetikum | |
| TW200716094A (en) | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |